These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 36505747)
21. Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells. Lok GT; Chan DW; Liu VW; Hui WW; Leung TH; Yao KM; Ngan HY PLoS One; 2011; 6(8):e23790. PubMed ID: 21858223 [TBL] [Abstract][Full Text] [Related]
22. Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells. Zhang X; Cheng L; Minn K; Madan R; Godwin AK; Shridhar V; Chien J Oncotarget; 2014 Nov; 5(22):11365-80. PubMed ID: 25426548 [TBL] [Abstract][Full Text] [Related]
23. FoxM1 promotes the migration of ovarian cancer cell through KRT5 and KRT7. Zhang Z; Tu K; Liu F; Liang M; Yu K; Wang Y; Luo Y; Yang B; Qin Y; He D; Jiang G; Huang O; Zou Y Gene; 2020 Oct; 757():144947. PubMed ID: 32659254 [TBL] [Abstract][Full Text] [Related]
24. FOXM1 Inhibition in Ovarian Cancer Tissue Cultures Affects Individual Treatment Susceptibility Ex Vivo. Brückner L; Reinshagen A; Hoang NA; Höhn AK; Lordick F; Bechmann I; Aktas B; Nel I; Kallendrusch S Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668819 [TBL] [Abstract][Full Text] [Related]
25. PCNA-associated factor P15 Jin C; Liu Z; Li Y; Bu H; Wang Y; Xu Y; Qiu C; Yan S; Yuan C; Li R; Diao N; Zhang Z; Wang X; Liu L; Kong B Int J Cancer; 2018 Dec; 143(11):2973-2984. PubMed ID: 30129654 [TBL] [Abstract][Full Text] [Related]
26. Targeting GRB7/ERK/FOXM1 signaling pathway impairs aggressiveness of ovarian cancer cells. Chan DW; Hui WW; Cai PC; Liu MX; Yung MM; Mak CS; Leung TH; Chan KK; Ngan HY PLoS One; 2012; 7(12):e52578. PubMed ID: 23285101 [TBL] [Abstract][Full Text] [Related]
27. A small molecule STAT3 inhibitor, LLL12, enhances cisplatin‑ and paclitaxel‑mediated inhibition of cell growth and migration in human ovarian cancer cells. Zhang R; Chen X; Fu S; Xu L; Lin J Oncol Rep; 2020 Sep; 44(3):1224-1232. PubMed ID: 32705214 [TBL] [Abstract][Full Text] [Related]
28. [Effects of Zengmian Yiliu Recipe combined cisplatin on the tumor inhibition rate in platinum-resistant ovarian cancer]. Qi C; Zhang QH; Li JX Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Jun; 32(6):817-21. PubMed ID: 22978111 [TBL] [Abstract][Full Text] [Related]
29. FOXM1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and mediates sensitivity to cisplatin in A549 cells via the JNK/mitochondrial pathway. Liu Y; Chen X; Gu Y; Zhu L; Qian Y; Pei D; Zhang W; Shu Y Neoplasma; 2015; 62(1):61-71. PubMed ID: 25563368 [TBL] [Abstract][Full Text] [Related]
30. FOXO and FOXM1 in cancer: the FOXO-FOXM1 axis shapes the outcome of cancer chemotherapy. Wilson MS; Brosens JJ; Schwenen HD; Lam EW Curr Drug Targets; 2011 Aug; 12(9):1256-66. PubMed ID: 21443467 [TBL] [Abstract][Full Text] [Related]
31. The TGFβ1-FOXM1-HMGA1-TGFβ1 positive feedback loop increases the cisplatin resistance of non-small cell lung cancer by inducing G6PD expression. Zhang R; Tao F; Ruan S; Hu M; Hu Y; Fang Z; Mei L; Gong C Am J Transl Res; 2019; 11(11):6860-6876. PubMed ID: 31814893 [TBL] [Abstract][Full Text] [Related]
32. TRIM24 aggravates the progression of ovarian cancer through negatively regulating FOXM1 level. Zhou HE; Pan SS; Han H Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10647-10656. PubMed ID: 31858531 [TBL] [Abstract][Full Text] [Related]
33. Inhibition of FOXM1 by thiostrepton sensitizes medulloblastoma to the effects of chemotherapy. Lin J; Zheng Y; Chen K; Huang Z; Wu X; Zhang N Oncol Rep; 2013 Oct; 30(4):1739-44. PubMed ID: 23912794 [TBL] [Abstract][Full Text] [Related]
34. MiR-214 inhibits cell migration, invasion and promotes the drug sensitivity in human cervical cancer by targeting FOXM1. Wang JM; Ju BH; Pan CJ; Gu Y; Li MQ; Sun L; Xu YY; Yin LR Am J Transl Res; 2017; 9(8):3541-3557. PubMed ID: 28861147 [TBL] [Abstract][Full Text] [Related]
35. FOXM1 Promotes Drug Resistance in Cervical Cancer Cells by Regulating ABCC5 Gene Transcription. Hou Y; Dong Z; Zhong W; Yin L; Li X; Kuerban G; Huang H Biomed Res Int; 2022; 2022():3032590. PubMed ID: 35141332 [TBL] [Abstract][Full Text] [Related]
36. LncRNA PVT1 epigenetically stabilizes and post-transcriptionally regulates FOXM1 by acting as a microRNA sponge and thus promotes malignant behaviors of ovarian cancer cells. Yi K; Hou M; Yuan J; Yang L; Zeng X; Xi M; Chen J Am J Transl Res; 2020; 12(6):2860-2874. PubMed ID: 32655815 [TBL] [Abstract][Full Text] [Related]
37. A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin. Zhang R; Yang X; Roque DM; Li C; Lin J PLoS One; 2021; 16(4):e0240145. PubMed ID: 33909625 [TBL] [Abstract][Full Text] [Related]
38. Novel Platinum Nanoclusters Activate PI3K/AKT/mTOR Signaling Pathway-Mediated Autophagy for Cisplatin-Resistant Ovarian Cancer Therapy. Zhang M; Yue H; Huang X; Wang J; Li Z; Deng X ACS Appl Mater Interfaces; 2022 Nov; 14(43):48502-48514. PubMed ID: 36261925 [TBL] [Abstract][Full Text] [Related]
39. Knockdown of the FoxM1 enhances the sensitivity of gastric cancer cells to cisplatin by targeting Mcl-1. Li X; Liang J; Liu YX; Wang Y; Yang XH; Bao-Hongluan ; Zhang GL; Du J; Wu XH Pharmazie; 2016 Jun; 71(6):345-8. PubMed ID: 27455555 [TBL] [Abstract][Full Text] [Related]
40. Medical therapy of advanced malignant epithelial tumours of the ovary. Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]